In this study, each treatment type was analyzed separately because determining the optimal proportion of patients who should receive a particular BC treatment modality according to clinical indicators using the GCCR data is not possible.
GCCR Policy and Procedure Manual for Reporting Facilities.
Patient-level variables were obtained from the GCCR and included race (white/AA/Other), ethnicity (Hispanic: yes/no), age at diagnosis, date of diagnosis, tumor-related information, type of first-course treatment received, last date of follow-up, and vital status at last follow-up.
Study subjects originated from the GCCR, and hence our research was restricted to data elements collected by the registry.
Those for whom stage was missing in the GCCR and/or Medicaid claims data and those who had more than one primary cancer site over their lifetime were also omitted (N=826).
To derive this measure, we used the disease stage data both from the GCCR and Medicaid claims for services received after the patients' enrollment.
The GCCR includes the Surveillance, Epidemiology, and End Results (SEER) Program summary stage, which can be used for all types of cancer.
The decision of whether we kept the stage data as found in the GCCR or changed it using claims was based on whether the woman enrolled in Medicaid within six months of her cancer diagnosis.